Compare SSTI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTI | ANIX |
|---|---|---|
| Founded | 1996 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.2M | 103.9M |
| IPO Year | 2017 | 2013 |
| Metric | SSTI | ANIX |
|---|---|---|
| Price | $8.36 | $3.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $8.84 | ★ $9.67 |
| AVG Volume (30 Days) | 89.4K | ★ 203.7K |
| Earning Date | 11-16-2026 | 09-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,753,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 46.25 | N/A |
| 52 Week Low | $5.42 | $2.32 |
| 52 Week High | $10.03 | $5.46 |
| Indicator | SSTI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 66.68 | 51.58 |
| Support Level | $8.21 | $2.77 |
| Resistance Level | $8.47 | $3.09 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 47.83 | 47.65 |
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes: ShotSpotter, the acoustic gunshot detection system; CrimeTracer, the foremost law enforcement search engine; CaseBuilder, a one-stop investigation management system; ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact; PlateRangerTM powered by Rekor, an automatic license plate recognition ("ALPR") and vehicle identification solution; SafePointe, an AI-based weapons detection system.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.